“It’s good news” for developing countries where angioplasty as first line of treatment for ischaemic symptoms is not an option. “When angioplasty can not be offered as early on as in the developed countries, giving patients antianginal therapies is a very valid alternative”. Dr. Rasha Al-Lamee tells Heart Asia social media editor Robin Chung the implications of her unprecedented trial in more remote parts of the world.
ORBITA is a blinded, multicentre randomised trial of percutaneous coronary intervention versus a placebo procedure for angina relief that was done at five study sites in the UK. 
<p>Link to the original paper: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32714-9</p>

Patient preferences for types of community-based cardiac rehabilitation programme

Heart Asia  aims to convey the best cardiology research and practice from the developing regions of the world to an international audience. The journal seeks to publish work from around the world with the Asia Pacific being a region of particular focus. A collaboration of the British Cardiovascular Society and BMJ, Heart Asia publishes original research, topical articles and analysis.
Content is currently free - just register here (http://goo.gl/8691xn) to gain access.
* The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.